Results 141 to 150 of about 1,103 (154)

Clinical safety and efficacy of bepotastine besilate ophthalmic solution to treat allergic conjunctivitis

Expert Review of Ophthalmology, 2010
The mast cell-stabilizer–antihistamine class of medications has become physicians’ first choice for treating seasonal allergic conjunctivitis owing to the rapid onset of action, long duration of effect and improved comfort. Bepotastine besilate ophthalmic solution 1.5% (Bepreve™, ISTA Pharmaceuticals, Inc., CA, USA) has recently been approved by the US
Gregg J Berdy, Heather S Oliff
openaire   +1 more source

Oral Administration of Bepotastine Besilate Suppressed Scratching Behavior of Atopic Dermatitis Model NC/Nga Mice

International Archives of Allergy and Immunology, 2007
<i>Background:</i> Pruritus is the most severe problem in atopic dermatitis. Even though its mechanism is still not fully understood, antihistamines have been prescribed for atopic dermatitis. <i>Objective:</i> To evaluate the effect of antihistamine on atopic dermatitis, we analyzed the scratching behavior in atopic dermatitis ...
Hideaki, Tanizaki, Naotomo, Kambe, Yuumi, Nakamura, Akane, Tanaka, Hiroshi, Matsuda, Yoshiki, Miyachi   +5 more
openaire   +2 more sources

Efficacy and Safety of Bepotastine Besilate in the Treatment of Chronic Urticaria

Nishi Nihon Hifuka, 2006
Minao FURUMURA, Yumiko KUBOTA, Juichiro NAKAYAMA   +2 more
openaire   +1 more source

Suppression by Bepotastine Besilate of Substance P-Induced Itch-Associated Responses Through the Inhibition of the Leukotriene B4 Action in Mice

European Journal of Pharmacology, 2006
Tsugunobu Andoh, Yasushi Kuraishi
exaly  

Characterization of Photodegradation Products of Bepotastine Besilate and in Silico Evaluation of Their Physicochemical, Absorption, Distribution, Metabolism, Excretion and Toxicity Properties

Journal of Pharmaceutical Sciences, 2020
Asit K Chakraborti, Prasad V. Bharatam, Saranjit Singh   +2 more
exaly  

Bepotastine besilate rapidly inhibits mite-antigen induced immediate reactions in atopic dermatitis

Journal of Dermatological Science, 2003
Takeshi, Nakahara, Kazunori, Urabe, Yoichi, Moroi, Keisuke, Morita, Masutaka, Furue   +4 more
openaire   +2 more sources

Time to Onset and Duration of Action of the Antihistamine Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% in Allergic Conjunctivitis: A Phase III, Single-Center, Prospective, Randomized, Double-Masked, Placebo-Controlled, Conjunctival Allergen Challenge Assessment in Adults and Children

Clinical Therapeutics, 2009
Mark B Abelson, Paul J Gomes
exaly  

Bepotastine Besilate OD Tablets Suppress Nasal Symptoms Caused by Japanese Cedar Pollen Exposure in an Artificial Exposure Chamber (OHIO Chamber)

Expert Opinion on Pharmacotherapy, 2009
Minoru Gotoh, Kimihiro Okubo, Kazuhiro Hashiguchi   +2 more
exaly  

Development of Novel Bepotastine Salicylate Salt Bioequivalent to the Commercial Bepotastine Besilate in Beagle Dogs

Drug Development and Industrial Pharmacy, 2013
Han-Gon Choi, Kwan Hyung Cho
exaly  

Bepotastine Besilate, a Highly Selective Histamine H1 Receptor Antagonist, Suppresses Vascular Hyperpermeability and Eosinophil Recruitment in in Vitro and in Vivo Experimental Allergic Conjunctivitis Models

Experimental Eye Research, 2010
Ikuyo Atsumi, Osamu Sakai, Tomoyuki Wada
exaly